The following information was compiled in August 2024 and is subject to change as new research is conducted and as new information becomes available:

Description: 5-Methyl etodesnitazene is a novel synthetic opioid bearing structural resemblance to etonitazene, etodesnitazene, and other nitazene analogues. 5-Methyl etodesnitazene was first detected in January 2024 by our laboratory and was confirmed in comparison to standard reference material.

Sample Source: AIDS Project of Southern Vermont In Collaboration with StreetCheck

Sample Appearance: White powder

Pharmacology: In vitro pharmacological data available for 5-methyl etodesnitazene show that this drug is an active opioid and is approximately 10x less potent than etonitazene, its 5-NO2 counterpart.

Toxicology: 5-Methyl etodesnitazene has been identified in two toxicology cases to date at the CFSRE.

Drug Materials: 5-Methyl etodesnitazene has been detected in one drug material to date at the CFSRE.

Demographics / Geographics: Drug material originated from Vermont and toxicology cases originated from North Carolina and Connecticut. 5-Methyl etodesnitazene was identified alongside fentanyl, NPS benzodiazepines (e.g., bromazolam), and other nitazene analogues (e.g., metonitazene).

Legal Status: 5-Methyl etodesnitazene is not currently scheduled in the United States.

Class: Opioid
 Appearance: White powder
 Formula: C23H31N3O
 MW: 365.5
 [M+]: 365
 [M+H]+: 366.2540
 IUPAC: 2-[2-[(4-ethoxyphenyl)methyl]-5-methyl-benzimidazol-1-yl]-N,N-diethyl-ethanamine
 Report Date: August 26, 2024